News | Cardiovascular Ultrasound | August 07, 2019

Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing

Study of more than 9,000 patients finds contrast group five times less likely to need repeat exam with earlier hospital discharges

Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing

August 7, 2019 — Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for ordering an inpatient transthoracic echocardiogram (TTE). Research presented at the 30th Annual American Society of Echocardiography (ASE) Scientific Sessions shows patients who received an echocardiogram with contrast were less likely to require repeat tests and had shorter hospitalizations overall. This study shows the value of contrast (ultrasound enhancing agent/UEA) for improving clinical care and potentially decreasing healthcare costs.

Lead author Katherine C. Lee, Piedmont Heart Institute and Georgia Institute of Technology, Atlanta, said, “The appropriate use of echocardiography is one of today’s most challenging issues, having significant implications for both the quality and cost of care for patients with heart failure. An echocardiogram is the recommended first diagnostic test for heart failure and also the most common test performed for heart failure. With this retrospective analysis, we looked to analyze the relationship between contrast echocardiography and repeat echo testing among 9,115 patients who were admitted to the hospital with the diagnosis of heart failure over a four-year period. We found that patients who received a contrast echocardiogram as their first test were five times less likely to require a repeat echo and were discharged earlier from the hospital than those who did not receive contrast. This result highlights the importance of quality imaging (namely contrast echocardiography) in improving patient care, with the added benefit of generating potential cost savings to hospitals nationwide.”  

Ultrasound contrast used to enhance echocardiographic images is not the same type of contrast used in invasive catheter-based procedures such as angiography. Ultrasound contrast is comprised of tiny microbubbles and is commercially available from three different vendors in the United States. It has no renal side effects, is rapidly metabolized and is safe for use, with the only side effect being rare allergic reactions (approximately 1/10,000, comparable to other imaging contrast agents).

For more information: www.asecho.org

Related Content

Vaping Impairs Vascular Function

Image courtesy of the American Heart Association

News | Magnetic Resonance Imaging (MRI) | August 21, 2019
Inhaling a vaporized liquid solution through an e-cigarette, otherwise known as vaping, immediately impacts vascular...
Jackson Memorial Hospital Holds Ribbon-cutting for New Cardiac Catheterization Labs
News | Angiography | August 21, 2019
Jackson Memorial Hospital in Miami celebrated the opening of two newly renovated cardiac catheterization suites during...
Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy
News | Women's Health | August 20, 2019
A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent...
ADHD Medication May Affect Brain Development in Children

Images of regions of interest (colored lines) in the white matter skeleton representation. Data from left and right anterior thalamic radiation (ATR) were averaged. Image courtesy of C. Bouziane et al.

News | Neuro Imaging | August 16, 2019
A drug used to treat attention-deficit/hyperactivity disorder (ADHD) appears to affect development of the brain’s...
First Patient Enrolled in World's Largest Brain Cancer Clinical Trial
News | Radiation Therapy | August 15, 2019
Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive...
Efficacy of Isoray's Cesium Blu Showcased in Recent Studies
News | Brachytherapy Systems | August 14, 2019
August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica
Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging

Image courtesy of Imago Systems

News | Mammography | August 14, 2019
Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year...
Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses
News | Artificial Intelligence | August 13, 2019
University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that...